ID30037A - Metoda untuk mereduksi tingkat serum trigliserida dan untuk menghambat angiogenesis menggunakan asam-asam indolalkanoat tersubstitusi - Google Patents

Metoda untuk mereduksi tingkat serum trigliserida dan untuk menghambat angiogenesis menggunakan asam-asam indolalkanoat tersubstitusi

Info

Publication number
ID30037A
ID30037A IDW00200101404A ID20011404A ID30037A ID 30037 A ID30037 A ID 30037A ID W00200101404 A IDW00200101404 A ID W00200101404A ID 20011404 A ID20011404 A ID 20011404A ID 30037 A ID30037 A ID 30037A
Authority
ID
Indonesia
Prior art keywords
trigliceridal
indolalicanic
acids
substituted
methods
Prior art date
Application number
IDW00200101404A
Other languages
English (en)
Inventor
Janet Sredy
Jorge Jacot
Original Assignee
Inst For Pharm Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst For Pharm Discovery Inc filed Critical Inst For Pharm Discovery Inc
Publication of ID30037A publication Critical patent/ID30037A/id

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IDW00200101404A 1998-12-01 1999-12-01 Metoda untuk mereduksi tingkat serum trigliserida dan untuk menghambat angiogenesis menggunakan asam-asam indolalkanoat tersubstitusi ID30037A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11039598P 1998-12-01 1998-12-01

Publications (1)

Publication Number Publication Date
ID30037A true ID30037A (id) 2001-11-01

Family

ID=22332786

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW00200101404A ID30037A (id) 1998-12-01 1999-12-01 Metoda untuk mereduksi tingkat serum trigliserida dan untuk menghambat angiogenesis menggunakan asam-asam indolalkanoat tersubstitusi

Country Status (30)

Country Link
US (5) US6555568B1 (id)
EP (1) EP1135124B1 (id)
JP (1) JP2002531398A (id)
KR (1) KR20010086075A (id)
CN (1) CN1368883A (id)
AP (1) AP2001002146A0 (id)
AT (1) ATE265210T1 (id)
AU (1) AU770925B2 (id)
BG (1) BG105531A (id)
BR (1) BR9915882A (id)
CA (1) CA2385845A1 (id)
CZ (1) CZ20011864A3 (id)
DE (1) DE69916881T2 (id)
DZ (1) DZ2953A1 (id)
EE (1) EE200100296A (id)
HK (1) HK1046372A1 (id)
HU (1) HUP0104953A3 (id)
ID (1) ID30037A (id)
IL (1) IL143247A0 (id)
MX (1) MXPA02003118A (id)
NO (1) NO20012690L (id)
OA (1) OA12035A (id)
PL (1) PL349016A1 (id)
SK (1) SK7352001A3 (id)
TN (1) TNSN99224A1 (id)
TR (1) TR200101539T2 (id)
TW (1) TW584560B (id)
WO (1) WO2000032180A2 (id)
YU (1) YU40101A (id)
ZA (1) ZA200104126B (id)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE269861T1 (de) * 1998-03-31 2004-07-15 Inst For Pharm Discovery Inc Substituierte indolalkansäure
TNSN99224A1 (fr) * 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
US6521659B2 (en) * 2000-03-02 2003-02-18 Institute For Pharmaceutical Discovery, Llc Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor
AU2001259668A1 (en) * 2000-05-09 2001-11-20 The Institute For Pharmaceutical Discovery Llc Methods for testing compounds useful for treating diabetic complications
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
WO2003000253A1 (en) 2001-06-20 2003-01-03 Wyeth Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
CA2509191A1 (en) 2002-12-10 2004-06-24 Wyeth Aryl, aryloxy, and alkyloxy substituted 1h-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
WO2004052853A2 (en) 2002-12-10 2004-06-24 Wyeth Substituted 3-alkyl and 3-arylalkyl 1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
MXPA05006287A (es) 2002-12-10 2005-09-08 Wyeth Corp Derivados de acido indoloxo-acetilaminoacetico sustituidos como inhibidores del inhibidor del activador de plasminogeno 1 (pai-1).
CN1726190A (zh) 2002-12-10 2006-01-25 惠氏公司 作为纤溶酶原激活物抑制剂-1(pai-1)的抑制剂的取代3-羰基-1h-吲哚-1-基乙酸衍生物
UA80453C2 (en) 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
EP1620088A4 (en) * 2003-04-28 2007-08-29 Bayer Pharmaceuticals Corp ACETIC INDOLE ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS
US7342039B2 (en) 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7141592B2 (en) 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7332521B2 (en) 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7582773B2 (en) 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
GB0324763D0 (en) * 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
JP4880591B2 (ja) 2004-06-04 2012-02-22 テバ ファーマシューティカル インダストリーズ リミティド イルベサルタンを含む医薬組成物
RU2007106868A (ru) 2004-08-23 2008-09-27 Вайет (Us) Оксазол-нафтиловые кислоты и их применение в качестве модуляторов ингибитора активатора плазминогена-1 (pai) для лечения тромбоза и сердечно-сосудистых заболеваний
US20060135540A1 (en) * 2004-11-30 2006-06-22 Jack Lin PPAR active compounds
US7531568B2 (en) * 2004-11-30 2009-05-12 Plexxikon, Inc. PPAR active compounds
EP1919866A2 (en) 2005-08-17 2008-05-14 Wyeth a Corporation of the State of Delaware Substituted indoles and use thereof
BRPI0615929A2 (pt) * 2005-09-07 2011-05-31 Plexxikon Inc compostos ativos de ppar, composição, kit e uso dos mesmos
KR20090042808A (ko) 2006-07-22 2009-04-30 옥사겐 리미티드 씨알티에이치2 길항제 활성을 갖는 화합물
PE20090159A1 (es) * 2007-03-08 2009-02-21 Plexxikon Inc COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
US7750027B2 (en) * 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
CN101932571B (zh) 2008-01-18 2014-04-23 奥克萨根有限公司 具有crth2拮抗活性的化合物
EP2265581A1 (en) 2008-01-22 2010-12-29 Oxagen Limited Compounds having crth2 antagonist activity
EP2240444A1 (en) 2008-01-22 2010-10-20 Oxagen Limited Compounds having crth2 antagonist activity
EP2424521A4 (en) 2009-04-29 2015-03-04 Amarin Pharmaceuticals Ie Ltd PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND CARDIOVASCULAR AGENT AND METHODS OF USE
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
GB201322273D0 (en) 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3557142A (en) 1968-02-20 1971-01-19 Sterling Drug Inc 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters
IE47592B1 (en) 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
JPS55167282A (en) 1979-06-12 1980-12-26 Fujisawa Pharmaceut Co Ltd Piperazine derivative or its salt and its preparation
US4283539A (en) 1979-12-18 1981-08-11 Pfizer Inc. Isoquinoline acetic acids
US4363912A (en) * 1980-12-15 1982-12-14 Pfizer Inc. Indole thromboxane synthetase inhibitors
US4442118A (en) * 1981-07-23 1984-04-10 Ayerst, Mckenna & Harrison, Inc. Aldose reductase inhibition by 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid
GB8607294D0 (en) 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
US4939140A (en) 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
ES2032749T3 (es) 1985-11-07 1993-03-01 Pfizer Inc. Acidos oxoftalazinil-aceticos heterociclicos.
US4960785A (en) 1988-12-16 1990-10-02 Pfizer Inc. Indolinone derivatives
WO1993012786A1 (en) 1986-07-10 1993-07-08 Howard Harry R Jr Indolinone derivatives
US4868301A (en) 1987-06-09 1989-09-19 Pfizer Inc. Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
US5064852A (en) * 1988-12-16 1991-11-12 Pfizer Inc. Indolinone derivatives
US4996204A (en) 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
FR2647676A1 (fr) 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
GB8916774D0 (en) * 1989-07-21 1989-09-06 Bayer Ag New indole derivatives,a process for their preparation and their use in medicaments
WO1991009019A1 (en) 1989-12-15 1991-06-27 Pfizer Inc. Substituted oxophthalazinyl acetic acids and analogs thereof
US5312829A (en) * 1990-05-21 1994-05-17 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives
US5236945A (en) 1990-06-11 1993-08-17 Pfizer Inc. 1H-indazole-3-acetic acids as aldose reductase inhibitors
US5116753A (en) * 1991-07-30 1992-05-26 The Salk Institute For Biological Studies Maintenance of pancreatic islets
GB9122590D0 (en) 1991-10-24 1991-12-04 Lilly Industries Ltd Pharmaceutical compounds
JP3195455B2 (ja) 1993-01-06 2001-08-06 ウェルファイド株式会社 キノリン−3−酢酸誘導体、その製造法と用途
US5391551A (en) 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
AU7634694A (en) 1993-08-20 1995-03-21 University Of Medicine And Dentistry Of New Jersey Bridged polycationic polymer-oligonucleotide conjugates and methods for preparing same
GB9317764D0 (en) * 1993-08-26 1993-10-13 Pfizer Ltd Therapeutic compound
US5641800A (en) 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors
TW401301B (en) * 1994-10-07 2000-08-11 Takeda Chemical Industries Ltd Antihypertriglyceridemic composition
US5700819A (en) 1994-11-29 1997-12-23 Grelan Pharmaceutical Co., Ltd. 2-substituted benzothiazole derivatives and prophylactic and therapeutic agents for the treatment of diabetic complications
IL117208A0 (en) * 1995-02-23 1996-06-18 Nissan Chemical Ind Ltd Indole type thiazolidines
JPH09165371A (ja) 1995-10-09 1997-06-24 Sankyo Co Ltd 複素環化合物を含有する医薬
ATE269861T1 (de) * 1998-03-31 2004-07-15 Inst For Pharm Discovery Inc Substituierte indolalkansäure
TNSN99224A1 (fr) * 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
US6521659B2 (en) * 2000-03-02 2003-02-18 Institute For Pharmaceutical Discovery, Llc Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor

Also Published As

Publication number Publication date
YU40101A (sh) 2005-07-19
JP2002531398A (ja) 2002-09-24
PL349016A1 (en) 2002-06-17
US20060074114A1 (en) 2006-04-06
BR9915882A (pt) 2001-08-21
AU2161600A (en) 2000-06-19
NO20012690D0 (no) 2001-05-31
BG105531A (en) 2001-12-31
ATE265210T1 (de) 2004-05-15
US6555568B1 (en) 2003-04-29
ZA200104126B (en) 2002-05-21
HUP0104953A2 (hu) 2002-07-29
HUP0104953A3 (en) 2002-08-28
TW584560B (en) 2004-04-21
CN1368883A (zh) 2002-09-11
US20030216452A1 (en) 2003-11-20
NO20012690L (no) 2001-07-27
AP2001002146A0 (en) 2001-06-30
OA12035A (en) 2006-05-02
TR200101539T2 (tr) 2001-12-21
HK1046372A1 (zh) 2003-01-10
CZ20011864A3 (cs) 2002-03-13
DZ2953A1 (fr) 2004-03-15
TNSN99224A1 (fr) 2005-11-10
EP1135124A2 (en) 2001-09-26
EE200100296A (et) 2003-02-17
US20100324105A1 (en) 2010-12-23
US20120065203A1 (en) 2012-03-15
CA2385845A1 (en) 2000-06-08
KR20010086075A (ko) 2001-09-07
WO2000032180A2 (en) 2000-06-08
DE69916881D1 (de) 2004-06-03
IL143247A0 (en) 2002-04-21
US6964980B2 (en) 2005-11-15
SK7352001A3 (en) 2002-06-04
WO2000032180A3 (en) 2000-11-16
EP1135124B1 (en) 2004-04-28
AU770925B2 (en) 2004-03-11
DE69916881T2 (de) 2005-02-03
MXPA02003118A (es) 2004-04-21

Similar Documents

Publication Publication Date Title
ID30037A (id) Metoda untuk mereduksi tingkat serum trigliserida dan untuk menghambat angiogenesis menggunakan asam-asam indolalkanoat tersubstitusi
ID29298A (id) Metode dan komposisi untuk mengobati apnea selama tidur
ID26104A (id) Metoda-metoda dan bahan-bahan untuk mengobati dan mencegah radang jaringan mukosa
ID22852A (id) Bahan-bahan biokontrol antifungi, proses untuk membuatnya dan memperlakukannya
ID26161A (id) Serat poliester dan metode untuk membuatnya
ID28728A (id) Komposisi dan proses pengkrepan
ID27614A (id) Metode dan radas untuk terapi gelombang
ID19290A (id) Turunan-turunan propiofenon dan proses pembuatannya
ID20996A (id) Lembaran penyeka dan metode untuk memproduksinya
ID24524A (id) Kombinasi penghambat reduktase aldosa dan penghambat fosforilase glikogen
ID23684A (id) Komposisi-polimer-organoclay dan pembuatannya
DE69712003D1 (de) Modifikation von xylanase zur Verbesserung von Thermophilicität, alkophilicität und thermostabilität
ID29013A (id) Ligan-ligan reseptor novel thiroid dan metode ii
ID21859A (id) Bahan lembaran serupa-kulit dan metode untuk memproduksi bahan tersebut
ID28258A (id) Metode dan aparatus untuk balok seimbang memperkuat sesitifitas
ATE264069T1 (de) Verstärkung von nahrungsmitteln
ID19385A (id) Adesif termosetting dan metoda pembuatannya
FI980246A (fi) Menetelmä keittimen käyttämiseksi ja keitin
ID18244A (id) Komposisi polipropilena dan metoda pembuatannya dan katalis untuk
ID19229A (id) Metode dan alat penginput huruf
TR199802394A3 (tr) Proteinleri stabilize etmek için gelistirilmis proses.
ID30135A (id) Komposisi-komposisi dan metode-metode untuk mengontrol serangga-serangga
ID28025A (id) Metode pembuatan aminonitril dan diamina
FI951101A (fi) 5-vinyyli- ja 5-etinyylikinoloni- ja -naftyridonikarboksyylihapot
ID18954A (id) Kopolimer, proses terhidrogenasi daripadanya, dan proses untuk memproduksinya